

Special Issue

Antiphospholipid Antibodies: Beyond Biomarkers

Message from the Guest Editors

Antiphospholipid antibodies are a group of antibodies targeting phospholipid–protein complexes, famously including the lupus anticoagulant (LA), anticardiolipin (aCL), and anti-beta-2-glycoprotein 1 (anti- β 2GPI) antibodies. Long-recognised for their strong association with thrombotic events and pregnancy complications, aPLs are increasingly implicated in the pathogenesis of a broader spectrum of conditions. These include autoimmune and rheumatic diseases, various cancers, and neurological disorders. This expanding understanding, highlighted by their elevated presence even during the COVID-19 pandemic, suggests a role for aPLs that extends far beyond mere biomarkers. For this Special Issue, we invite papers that explore the multifaceted roles of aPLs. Submissions covering the following topics:

- aPLs as novel biomarkers in diverse diseases.
- The pathogenic mechanisms mediated by aPLs in various conditions.
- Innovations in laboratory testing and optimisation for aPL detection.
- Clinical, epidemiological, or basic science investigations shedding new light on aPLs.

We look forward to receiving your contributions on these crucial antibodies.

Guest Editors

Dr. Md Asiful Islam

Department of Biomedical Science and Physiology, School of Pharmacy and Life Sciences, University of Wolverhampton, Wolverhampton WV1 1LY, UK

Prof. Dr. Przemysław J Kotyla

Department of Internal Medicine Rheumatology and Clinical Immunology, Faculty of Medical Sciences in Katowice, Medical University of Silesia, 40-635 Katowice, Poland

Deadline for manuscript submissions

31 January 2027



Antibodies

an Open Access Journal
by MDPI

Impact Factor 3.3
CiteScore 4.9
Indexed in PubMed



mdpi.com/si/252984

Antibodies
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
antibodies@mdpi.com

[mdpi.com/journal/
antibodies](https://mdpi.com/journal/antibodies)





Antibodies

an Open Access Journal
by MDPI

Impact Factor 3.3
CiteScore 4.9
Indexed in PubMed



[mdpi.com/journal/
antibodies](https://mdpi.com/journal/antibodies)



About the Journal

Message from the Editor-in-Chief

Antibodies is a relatively new journal with a major focus on quick dissemination of knowledge related to antibodies, especially how to quickly translate basic research results to therapeutic applications. Because it covers all areas related to antibodies unexpected connections between different areas could be made, leading to major discoveries and opening new fields of research and development. This is enhanced by the large readership of the many antibody-related areas of research. A specific priority area is human monoclonal antibodies for therapy of diseases and aging.

Editor-in-Chief

Prof. Dr. Arne Skerra

Institute of Biological Chemistry, Technical University Munich, Emil-Erlenmeyer-Forum 5, 85350 Freising-Weihenstephan, Germany

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, ESCI (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

CiteScore - Q2 (Immunology and Allergy)